Spots Global Cancer Trial Database for mcl
Every month we try and update this database with for mcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years | NCT05406154 | Mantle Cell Lym... | 60 Years - | Peking University Third Hospital | ||
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma | NCT00445341 | Lymphoma | Flavopiridol | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00878254 | Mantle-Cell Lym... | G-CSF Rituximab Cyclophosphamid... Cytarabine Doxorubicin Etoposide Ifosfamide Leucovorin Mesna Methotrexate Vincristine | 18 Years - | University of Miami | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL | NCT01737177 | Mantle Cell Lym... | Bendamustine, L... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma | NCT05214183 | MCL Mantle Cell Lym... | Acalabrutinib-r... | 60 Years - | Nordic Lymphoma Group | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| The Role of 18F-FDG-PET for Staging and Prognostication | NCT04600804 | Mantle Cell Lym... | 18 Years - | Fondazione Italiana Linfomi - ETS | ||
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | NCT03112174 | Mantle-Cell Lym... | Ibrutinib Venetoclax Placebo Oral ta... | 18 Years - | Pharmacyclics LLC. | |
| "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | NCT05888701 | Mantle-cell Lym... B Cell Chronic ... | 18 Years - | University of Milano Bicocca | ||
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma | NCT00294632 | Lymphoma | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | NCT00114738 | Lymphoma, Mantl... Mantle Cell Lym... | Rituximab (R) EPOCH Bortezomib (B) Bortezomib Bortezomib or o... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | NCT03786926 | Lymphoma | HMPL-689 | 18 Years - | Hutchmed | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | NCT01090973 | Non-Hodgkin's L... | LBH589 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) | NCT01926665 | Lymphoma | Carfilzomib Dexamethasone | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | NCT03295240 | Mantle Cell Lym... Lymphoma | BR-I (bendamust... VEN (Venetoclax... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00878254 | Mantle-Cell Lym... | G-CSF Rituximab Cyclophosphamid... Cytarabine Doxorubicin Etoposide Ifosfamide Leucovorin Mesna Methotrexate Vincristine | 18 Years - | University of Miami | |
| Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years | NCT05429918 | Mantle Cell Lym... | 18 Years - 65 Years | Peking University Third Hospital | ||
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | NCT00114738 | Lymphoma, Mantl... Mantle Cell Lym... | Rituximab (R) EPOCH Bortezomib (B) Bortezomib Bortezomib or o... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | NCT00861510 | Lymphoma, Mantl... Leukemia, Lymph... Leukemia, Hairy... Waldenstrom Mac... Multiple Myelom... | ON01910 Na | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | NCT02793583 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... | Ublituximab Umbralisib Bendamustine | 18 Years - | TG Therapeutics, Inc. | |
| The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | NCT03295240 | Mantle Cell Lym... Lymphoma | BR-I (bendamust... VEN (Venetoclax... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | NCT03625037 | DLBCL High-grade B-ce... Primary Mediast... FL MCL Small Lymphocyt... Marginal Zone L... | Epcoritamab | 18 Years - | Genmab | |
| A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT00875667 | Mantle Cell Lym... Lymphoma, Mantl... | Lenalidomide Investigators c... | 18 Years - | Celgene | |
| Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | NCT04903197 | Non-Hodgkin Lym... | VAY736 lenalidomide | 18 Years - | Novartis | |
| Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT04477486 | Mantle Cell Lym... | Ibrutinib Venetoclax | 20 Years - | AbbVie | |
| A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers | NCT01117142 | Lymphoma, Mantl... CLL (Chronic Ly... Monoclonal B-Ce... Healthy Volunte... Small Lymphocyt... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | NCT04277637 | Mature B-Cell M... | BGB-11417 Zanubrutinib obinutuzumab | 18 Years - | BeiGene | |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | NCT03893682 | Chronic Lymphoc... Small Lymphocyt... Non-Hodgkin's L... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | NCT05365659 | B-cell Non-Hodg... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... B-cell Lymphoma | IKS03 | 18 Years - | Iksuda Therapeutics Ltd. | |
| Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) | NCT01504776 | Mantle Cell Lym... | Panobinostat Bortezomib | 18 Years - | Augusta University | |
| Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL | NCT01662050 | Mantle Cell Lym... | Rituximab, Bend... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | NCT05414162 | DLBCL Multiple Myelom... Cytokine Releas... Myocarditis CAR T-cell Ther... ALL PCBCL Follicular Lymp... MCL | Cardiac MRI | 18 Years - | University Hospital, Bonn | |
| The Role of 18F-FDG-PET for Staging and Prognostication | NCT04600804 | Mantle Cell Lym... | 18 Years - | Fondazione Italiana Linfomi - ETS | ||
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | NCT05370430 | Relapsed or Ref... | BAFFR-CAR T cel... | 18 Years - | PeproMene Bio, Inc. | |
| The Role of 18F-FDG-PET for Staging and Prognostication | NCT04600804 | Mantle Cell Lym... | 18 Years - | Fondazione Italiana Linfomi - ETS | ||
| Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | NCT02603445 | Follicular Lymp... | BCL201 Idelalisib | 18 Years - | Novartis | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT04477486 | Mantle Cell Lym... | Ibrutinib Venetoclax | 20 Years - | AbbVie | |
| An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | NCT02213926 | Mantle Cell Lym... | ACP-196 (acalab... | 18 Years - 130 Years | Acerta Pharma BV | |
| The Role of 18F-FDG-PET for Staging and Prognostication | NCT04600804 | Mantle Cell Lym... | 18 Years - | Fondazione Italiana Linfomi - ETS | ||
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | NCT05888701 | Mantle-cell Lym... B Cell Chronic ... | 18 Years - | University of Milano Bicocca | ||
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | NCT05888701 | Mantle-cell Lym... B Cell Chronic ... | 18 Years - | University of Milano Bicocca | ||
| Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL | NCT01662050 | Mantle Cell Lym... | Rituximab, Bend... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT03328078 | Relapsed Hemato... Refractory Hema... Relapsed Primar... Refractory Prim... | Emavusertib ibrutinib | 18 Years - | Curis, Inc. | |
| A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT00875667 | Mantle Cell Lym... Lymphoma, Mantl... | Lenalidomide Investigators c... | 18 Years - | Celgene | |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | NCT06192888 | Mantle Cell Lym... MCL | Glofitamab Obinutuzumab Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | NCT02269085 | Lymphoma | Ibrutinib Carfilzomib Phone Calls | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
